Knowledge Library

How Does It Work? | RNAi

As part of our dedication to providing an #openaccess platform, so our entire ecosystem can come together to share #science & #collaborate to better the lives of all #patientsfirst. We’ve created MoA animations in our new series exploring biotech topics on a molecular level. Protein malfunctions cause many diseases, but a new approach is emerging …Read More >

Resource Type: Video
Resource Topic: Autoimmune and Inflammatory Diseases, Cardiovascular & Metabolic Diseases, Central Nervous System & Pain, DRUG DISCOVERY AND INNOVATION, Gene Therapies, Liver Diseases, Metabolic Diseases, Oligonucleotides, Oncology, Ophthalmology, Rare Diseases, Target Identification and Validation

VIEW

NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis

Resource Type: Webinar
Resource Topic: Biomarkers, Lead Optimization, Liver Diseases, Metabolic Diseases, NASH

VIEW

Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets

Resource Type: Webinar
Resource Topic: Biomarkers, Hit Finding, Hit-to-Lead, in silico services, Liver Diseases, Oncology, Target Identification and Validation

VIEW

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

Resource Type: Article, Blog
Resource Topic: Biomarkers, Candidate Selection, Liver Diseases, Metabolic Diseases, NASH

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!